Spring til hovednavigation Spring til søgning Spring til hovedindhold

Impella RP Versus Pharmacologic Vasoactive Treatment in Profound Cardiogenic Shock due to Right Ventricular Failure

  • Jakob Josiassen*
  • , Ole K.L. Helgestad
  • , Nanna L.J. Udesen
  • , Ann Banke
  • , Peter H. Frederiksen
  • , Henrik Schmidt
  • , Lisette O. Jensen
  • , Christian Hassager
  • , Jacob E. Møller
  • , Hanne B. Ravn
  • *Corresponding author af dette arbejde

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Abstract

The aim was to translationally compare a pharmacologic strategy versus treatment with the Impella RP in profound RV cardiogenic shock (CS). The pigs were allocated to either vasoactive therapy with norepinephrine (0.10 μg/kg/min) for the first 30 min, supplemented by an infusion of milrinone (0.4 μg/kg/min) for additional 150 min, or treatment with the Impella RP device for 180 min. Total RV workload (Pressure-volume-area × heart rate*103(mmHg/min)) remained unaffected upon treatment with the Impella RP and increased in the vasoactive group (CS 179[147;228] to norepinephrine 268[247;306](p = 0.002 compared to Impella RP) and norepinephrine + milrinone 366[329;422] (p = 0.002 compared to Impella RP). A trend towards higher venous cerebral oxygen saturation was observed with norepinephrine than Impella RP (Impella RP 51[47;61]% vs norepinephrine 62[57;71]%; p = 0.07), which became significantly higher with the addition of milrinone (Impella RP 45[32;63]% vs norepinephrine + milrinone 73[66;81]%; p = 0.002). The Impella RP unloaded the failing RV. In contrast, vasoactive treatment led to enhanced cerebral venous oxygen saturation.

OriginalsprogEngelsk
TidsskriftJournal of Cardiovascular Translational Research
Vol/bind14
Sider (fra-til)1021–1029
ISSN1937-5387
DOI
StatusUdgivet - 2021

Bibliografisk note

Funding Information:
This work was supported by the Danish Heart Foundation, Abiomed, and the Jørgen Møller Foundation. The funders had no influence on any aspects of current work.

Funding Information:
Professor Møller has received a research grant from Abiomed. The remaining authors declare no competing interests.

Publisher Copyright:
© 2021, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Finansiering

This work was supported by the Danish Heart Foundation, Abiomed, and the Jørgen Møller Foundation. The funders had no influence on any aspects of current work. Professor Møller has received a research grant from Abiomed. The remaining authors declare no competing interests.

Citationsformater